AstraZeneca finds faslodex better than arimidex in treating metastatic breast cancer
AstraZeneca has found that faslodex 500mg (fulvestrant) is demonstrating better results than arimidex 1mg (anastrozole) while treating locally-advanced or metastatic breast cancer in post-menopausal women, who have not had prior hormonal treatment fo…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Arimidex | AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Hormones | Men | Menopause | Pharmaceuticals | Women